Citation Impact
Citing Papers
Alterations of the bile microbiome in primary sclerosing cholangitis
2019
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
2022
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices
2020
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
2020
Burden of liver diseases in the world
2018 Standout
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis
2020
Interaction between microbiota and immunity in health and disease
2020 Standout
Gut microbiome, liver immunology, and liver diseases
2020
Gut microbiome and health: mechanistic insights
2022 Standout
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
2020
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
2020
Non-alcoholic fatty liver disease
2021 Standout
Global burden of liver disease: 2023 update
2023 Standout
Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis
2021
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States
2022
Advances in functional and molecular MRI technologies in chronic liver diseases
2020
A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis
2020
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
2021
Primary sclerosing cholangitis – a comprehensive review
2017
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
2020 StandoutNobel
Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience
2020
Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease
2019
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
2020
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
2020
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Works of Peter Eddowes being referenced
Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study
2018
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
2019
Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner
2017
Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease
2017